Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 2/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
| ▸ | APP | P05067 | 6/20 | 0.65 |
| ▸ | HTR1A | P08908 | 2/20 | 0.63 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.63 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.63 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.63 |
| ▸ | RXRA | P19793 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | IDO1 | P14902 | 2/20 | 0.55 |
| ▸ | AGXT | P21549 | 2/20 | 0.55 |
| ▸ | LTA4H | P09960 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12301149 | 0.89 | ABCB1 (0.60) | ABCB1NPC1RAB9AAPPHTR1A | |
| SCHEMBL12358221 | 0.87 | NPC1 (0.65) | ABCB1NPC1RAB9AAPPHTR1A | |
| SCHEMBL16019017 | 0.87 | MAPT (0.66) | ABCB1NPC1RAB9AAPPHTR1A | |
| SCHEMBL7565429 | 0.87 | ABCB1 (0.59) | ABCB1NPC1RAB9AAPPHTR1A | |
| SCHEMBL4518756 | 0.87 | APP (0.60) | ABCB1NPC1RAB9AAPPHTR1A | |
| SCHEMBL7914167 | 0.87 | ABCB1 (0.59) | ABCB1NPC1RAB9AAPPHTR1A | |
| SCHEMBL30145233 | 0.87 | ABCB1 (0.59) | ABCB1NPC1RAB9AAPPHTR1A | |
| SCHEMBL11083926 | 0.87 | APP (0.65) | ABCB1NPC1RAB9AAPPHTR1A | |
| SCHEMBL22193705 | 0.86 | ABCB1 (0.70) | ABCB1NPC1RAB9AAPPHTR1A | |
| SCHEMBL2555868 | 0.84 | LIPE (0.73) | ABCB1NPC1RAB9AAPPHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140256697-A1 | CEPHEM DERIVATIVE HAVING CATECHOL GROUP | SHIONOGI & CO., LTD. (JP) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256697-A1 | CEPHEM DERIVATIVE HAVING CATECHOL GROUP | COMT, CEP170, SLC6A3 | ABCB1 105/4885NPC1 692/4885RAB9A 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.